Update on bipolar disorder: How to better predict response to maintenance therapy
Current Psychiatry. 2002 April;01(04):40-47
April 1, 2002|Psychiatry
Author and Disclosure Information
What does current evidence show regarding maintenance treatment with lithium, divalproex, carbamazepine, lamotrigine, or other agents? How well can you predict response? Which therapy will stop subsyndromal symptoms? The answers are here.
Dr. McElroy reports that she receives grant/research support from and serves as a consultant to Abbott Laboratories, Elan Pharmaceuticals, Cephalon Inc. GlaxoSmithKline, and Eli Lilly and Co. She also receives grant/research support from Forest Pharmaceuticals and Solvay Pharmaceuticals, and serves as a consultant to Bristol-Myers Squibb Co., Ortho-McNeil Pharmaceutical, and Janssen Pharmaceutica.
Dr. Nelson reports no financial relationship with any company whose products are mentioned in this article.
